Improved and large-scale synthesis of 10-methyl-aplog-1, a potential lead for an anticancer drug by Kikumori, Masayuki et al.
Title Improved and large-scale synthesis of 10-methyl-aplog-1, apotential lead for an anticancer drug
Author(s)Kikumori, Masayuki; Yanagita, Ryo C.; Irie, Kazuhiro
CitationTetrahedron (2014), 70(52): 9776-9782
Issue Date2014-12
URL http://hdl.handle.net/2433/192773



































































Improved and Large-Scale Synthesis of 10-Methyl-Aplog-1, a Potential Lead for an 
Anticancer Drug 
 
Masayuki Kikumoria, Ryo C. Yanagitab, and Kazuhiro Iriea, * 
 
aDivision of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, 
Kyoto 606-8502, Japan.  bDepartment of Applied Biological Science, Faculty of Agriculture, 
Kagawa University, Kagawa 761-0795, Japan 




10-Methyl-aplog-1 (1), a simplified analog of tumor-promoting aplysiatoxin, is a potential lead 
for cancer therapy that exhibits marked and selective growth inhibitory effects against several 
human cancer cell lines and negligible tumor-promoting activity in vivo.  However, more 
detailed evaluations of its toxicity and anticancer activity in vivo are hampered by supply 
problems associated with a non-optimal synthetic method.  We here addressed this issue 
through a more practical and reliable synthetic method that afforded several hundred milligrams 
of 1 with high purity (>98%) in 23 steps from commercially available m-hydroxycinnamic acid 
with an overall yield of 1.1%.  The utilization of two key reactions, substrate-controlled 
epoxidation and the oxidative cleavage of alkene with a free hydroxyl group, successfully 
reduced the existing five synthetic steps and markedly improved the handling of large amounts 
of intermediates.  We also demonstrated for the first time that such an analog was synthetically 
accessible in reliable quantities and also that this large supply could advance in vivo trials for 
the treatment of cancer. 
 




     The family of enzymes known as protein kinase C (PKC) has been widely recognized as 
an attractive target for treating intractable diseases such as cancer1, Alzheimer’s disease (AD)2, 













Fig. 1.  
Structures of naturally occurring tumor promoters and simplified analogs of aplysiatoxin. 
 
events including differentiation, proliferation, and apoptosis.  Thus, natural PKC activators 
such as phorbol esters, ingenol esters, teleocidins, and aplysiatoxins may serve as therapeutic 
leads (Fig. 1).  Although 12-O-tetradecanoylphorbol 13-acetate (TPA) and ingenol 3-angelate 
have already been evaluated in clinical trials for several cancers,4,5 their therapeutic use has been 
impeded by low natural abundance, structural complexity, difficulties associated with their 
synthesis and modification, as well as their undesired side effects such as tumor-promoting and 
severe inflammatory activities. 
      Bryostatin 1 (bryo-1), a lead member of this family, is a fascinating and mysterious 
PKC activator without tumor-promoting activity in vivo.  Bryo-1 has been investigated for 
anticancer activity in at least 43 phase I and phase II clinical trials,6,7 where it demonstrated an 
ability to enhance the effects of some anticancer drugs at remarkably low doses (~50 µg/m2, or 
~1–1.5 mg per 8-week treatment cycle).  Moreover, bryo-1 improved learning and memory in 
animal models,8 and its therapeutic potential for Alzheimer’s disease and other 
neurodegenerative disorders attracted much attention.  Despite the promising biological 
properties of bryo-1, further studies on its unique mode of action and the clinical development 
have been hampered by its limited availability.  Recently, function oriented synthesis of the 
simplified analogs of bryo-1 have been carried out to address these problems.9,10 
     As an alternative approach, we developed 10-methyl-aplog-1 (1, Scheme 1), a simplified 
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Fig. 2.  Efficacy profiles of aplog-1, 10-methyl-aplog-1 (1), and several anti-cancer drugs.  
Data for these anti-cancer drugs were retrieved from the NCI/NIH public database 
(http://dtp.nci.nih.gov/).  A) “Fingerprints” against 26 human cancer cell lines.  Data for the 
following cell lines are listed in top-to-bottom order: Breast (MDA-MB-231/ATCC, MCF7); 
Prostate (DU-145, PC-3); Renal (ACHN); Ovarian (SK-OV-3, OVCAR-8, OVCAR-5, 
OVCAR-4, OVCAR-3); Melanoma (LOX IMVI); Central nervous system (U251, SNB-75, 
SF-539, SF-295, SF-268); Colon (KM12, HT29, HCT-15, HCT-116, HCC-2998); Non-small 
cell lung (NCI-H522, NCI-H460, NCI-H23, NCI-H226, A549/HTCC).  MG-MID, log GI50 
(log M, 50% cell growth inhibition) mean-graph midpoint.  B) A correlation matrix plot based 
on Pearson correlation coefficients between log GI50 values of aplogs and anti-cancer drugs 
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(MG-MID) (−5.23) (−6.66) (−8.13) (−7.89)
 5 
cancer cell lines and negligible tumor-promoting activity in mouse skin.11  Extensive growth 
inhibitory assays against 39 human cancer cell lines revealed that its anti-proliferative activity 
was cell line selective and also that its efficacy profile (fingerprint) was completely different 
from that of any type of anticancer agent available today, thereby supporting its unique mode of 
action and a new aspect of anticancer drug development (Fig. 2). 
     The analog 1 lacked the chiral methyl groups at positions 4, 12, and 30, the methoxy 
group at position 15 as well as the bromine atom at position 21 to decrease hydrophobicity, and 
replaced the labile hemiacetal hydroxyl group at position 3 with a hydrogen atom to increase 
chemical stability.  This structural simplification successfully eliminated over 20 synthetic 
steps and reduced barriers against its practical synthesis without attenuating its marked 
anti-proliferative activities and ability to activate PKCs.12  Despite these prospective features 
as a future therapeutic candidate, the inefficiency of our first-generation synthesis of 1 
prevented further experiments on animals and structural optimization for clinical use.  To 
satisfy these needs, we attempted to develop a more practical synthetic method for 1 for the 
preparation of sufficient amounts of the sample in order to examine its toxicity and anticancer 
effects in an animal model. 
  
2. Results and discussion 
     From a synthetic perspective, we maintained the triply convergent route applied in our 
first-generation synthesis, dissecting 1 at two ester linkages to generate subunits A and B.  The 
further division of fragment A provided two subunits, C and D (Scheme 1).  Our previous 
attempt to construct an anti, anti-stereotriad in subunit C using Smith’s iodocarbonate 
cyclization strategy13 required three steps from a homoallyl alcohol (5) and also gave 
unsatisfactory results with poor stereoselectivity and a low yield.  Moreover, subsequent 
methanolysis of the carbonate moiety required careful control of the reaction temperature in 
order to prevent opening of the epoxide ring.11  This inefficient and complicated process 
severely disturbed the large-scale preparation of 1; thus, its improvement was inevitable.  We 
decided to utilize the one-step hydroxyl-directed epoxidation of 5.  Such an approach could 
facilitate the handling of large-scale intermediates. 
     The synthesis of 1 started with the hydrogenation of m-hydroxycinnamic acid (2), 
followed by esterification, protection of the phenol group as a benzyl ether, reduction, and 
bromination to provide a known bromide (3) in 91% yield from 2.  In practice, the first four 













Scheme 1.  Retrosynthetic analysis of 1. 
 
was purified by column chromatography before the next step.  This procedure could be 
performed routinely on a 20-g scale.  The substitution of the known bromide with diethyl 
malonate gave a diester, which was decarbalkoxylated without purification to produce an ester 
(4) in 62 % yield.  Partial reduction of 4 to an aldehyde was accomplished on a 5-g scale, and 
the aldehyde was immediately used for asymmetric Brown crotylation14 to furnish a homoallyl 
alcohol (5) in 56–84% yield from 4.  The vanadium-catalyzed epoxidation15 of 5 generated a 
diastereomeric mixture of epoxyalcohols (anti, anti : syn, anti = 3:1).  Although it was difficult 
to completely separate them, a sufficient amount of pure desired epoxyalcohol (6) with an anti, 
anti-stereotriad was obtained by careful and repeated normal phase chromatography.  
Therefore, 6 was obtained in 57% yield from 5.  The secondary hydroxyl group of 6 was 
protected as a p-methoxyphenylmethyl (MPM) ether (71%).  A total of 9.6 g of subunit C (7) 
was obtained in 11 steps with an overall yield of 17% from 2. 
     We previously reported that successful coupling of the epoxide (7) with the known 
dithiane (8)16 required strict dry conditions.  Normal vacuum drying was inappropriate for 
dehydrating large amounts of the compound, and the amount was limited to approximately 70 
mg.  The azeotropic dehydration of large-scale materials using toluene also appeared to be 
inapplicable because the benzyl site in the resulting toluene could be lithiated by n-butyl lithium 
to react with electrophiles.  To overcome this problem, 200 mg of 7 and 245 mg of 8 were 
charged in 10-mL flasks separately, spread on the inside walls of the flasks, dried in a vacuum 




































Scheme 2.  Synthesis of 1.  Reagents and conditions:  (a) (1) 10% Pd/C, H2, MeOH; (2) 
SOCl2, MeOH; (3) BnBr, K2CO3, Acetone; (b) (1) LiAlH4, THF; (2) CBr4, PPh3, CH2Cl2; 91% 
from 2 in five steps.  (c) (1) Diethyl malonate, NaH, DMF; (2) LiCl, DMSO, H2O; 62% in two 
steps.  (d) (1) DIBAL, Toluene; (2) trans-2-Butene, KOt-Bu, n-BuLi, (–)-Ipc2BOMe, BF3·OEt2, 
THF; 74% in two steps.  (e) VO(acac)2, t-BuOOH, CH2Cl2, 57%.  (f) MPM-Cl, NaH, DMF, 
THF, 71%.  (g) 8, n-BuLi, THF, 94%.  (h) (1) DDQ, CH2Cl2; (2) TBAF·3H2O, THF; 93% in 
two steps.  (i) (1) SO3·Pyr, DMSO, Et3N, CH2Cl2; (2) TiCl4, Ti(Oi-Pr)4, Ag2O, (S)-BINOL, 
Allyl-SnBu3, CH2Cl2; 60% in two steps.  (j) TFA, H2O, THF, 48%.  (k) Selectfluor®, MeCN, 
H2O; 12, 56%; 13, 22%.  (l) PPTS, MeCN, CH2Cl2; 12, 73%; 13, 24%.  (m) 14, TCB-Cl, Et3N, 
DMAP, Toluene, 93%.  (n) DDQ, pH 7 buffer, CH2Cl2, 87%.  (o) KMnO4, NaIO4, t-BuOH, 
pH 7 buffer, 71%.  (p) TCB-Cl, Et3N, DMAP, Toluene, 82%.  (q) 10% Pd/C, H2, EtOH, 83%.  
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utilized a 2.0 equivalent of 8, a 1.5 equivalent was sufficient to consume all of 7 without a 
prolonged reaction time.  The application of this method succeeded in producing the coupling 
product at an excellent yield (94%). 
     Oxidation of the coupling product at the benzyl site of the MPM ether by treating 1 
equivalent of DDQ formed anisylidene acetal to protect the secondary hydroxyl group.  We 
found that the addition of 4 Å molecular sieves to maintain the dehydrated condition was not 
required for intramolecular acetalization and also simplified the handling of this reaction.  
Desilylation followed by the Parikh-Doering oxidation17 of the alcohol (9) provided an aldehyde.  
Maruoka’s asymmetric allylation18 of the aldehyde on a 3-g scale and simple purification by 
normal phase column chromatography provided a homoallyl alcohol (10) in 50–66% yield, as 
well as a mixture of (S)-BINOL and the recovered aldehyde.  The mixture was further purified 
by reverse phase column chromatography to give pure aldehyde, which was again used for 
asymmetric allylation.  Collectively, 60% of the total aldehyde was converted to 10. 
     Deprotection of the anisylidene acetal was challenging because of the high stability of the 
acetal moiety.  Our screening for an optimal method for the detachment of the anisylidene 
acetal suggested that acid-catalyzed hydrolysis using the TFA/H2O/THF condition was the best 
because this condition made the purification of the product simpler than previous method.  The 
application of this condition on a 2-g scale provided a triol (11) in 41–59% yield and recovered 
the acetal (10) in 34–45%.  Collectively, 3.18 g (5.30 mmol) of 11 was obtained in 48% yield 
from 7.89 g (11.0 mmol) of initial 10.  We found that a careful and accurate workup to 
neutralize the reaction mixture was essential because severe decomposition of the substrate and 
product occurred during concentration under acidic condition. 
     The use of selectflour®19, an electrophilic fluorinating reagent, more efficiently achieved 
the simultaneous cleavage of 1,3-dithiane and spiroketalization than the conventional method 
using hazardous mercury (II).  The desired spiroketal (12) and undesired one (13) were 
obtained in 51–60% and 22–25% yields, respectively.  Treatment of 13 with PPTS produced a 
3:1 mixture of 12 and 13, and this equilibrium reaction was repeated again.  Collectively, 1.89 
g of 12 was obtained in 73% yield from the triol (11).  A total of 737 mg of 12 was carried 
forward to the next steps. 
     Condensation of the spiroketal (12) with the known carboxylic acid (14) was achieved 
using Yamaguchi’s method20.  Detachment of the MPM group using the DDQ/CH2Cl2/H2O 
condition on a several hundred milligram scale resulted in the unexpected isomerization of at 
least 30% of the spiroketal, presumably because the prolonged reaction time led to the 
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decomposition of DDQ to acidify the reaction mixture.  Attempts to maintain neutral 
conditions by employing a phosphate buffer (pH 7.4) instead of distilled water successfully 
prevented this severe isomerization. 
     Although our previous experiment suggested that switching of the protecting group from 
a MPM group to a triethylsilyl group was successful for providing the corresponding carboxylic 
acid, oxidative cleavage of the olefin group in the corresponding silyl ether resulted in a low 
yield (22%), presumably because of its poor solubility in the solvent (t-BuOH/pH 7 phosphate 
buffer = 1:1).  The utilization of a more hydrophilic olefin (16) with a free hydroxyl group 
produced a carboxylic acid (17) in good yield (71%), and oxidation of the free secondary 
hydroxyl group did not proceed under this condition.  This OH-free method omitted the 
protection/deprotection steps, and markedly improved the efficiency of the oxidative cleavage 
step. 
     Yamaguchi’s macrolactonization20 of the seco-acid (17) was performed at 2 mM to 
efficiently produce a lactone (18) (82%), and the production of a dimer was not confirmed.  
We also showed that a prolonged time for adding a solution of a mixed anhydride into a 
solution of DMAP was not needed for the desired intramolecular reaction; that is, the total time 
for the reagent adding could be shortened to only 15 minutes from 5 hours.  Finally, removal 
of two benzyl groups, and purification by convenient normal phase column chromatography 
provided 287 mg of 10-methyl-aplog-1 (1) in 23 steps from m-hydroxycinnamic acid with an 
overall yield of 1.1%.  An additional 500 mg of 1 could be obtained by treating the other 1.15 
g of 12 in a similar manner.  1H, 13C NMR, specific optical rotation, and FAB-MS data 
coincided with previous findings.11  Its purity was confirmed to be more than 98% by 1H, 13C 
NMR data and HPLC analysis (Supporting Information).  1H NMR data of 3, 4, 7, 10, 12, and 
15 also agreed with previous findings.11 
     In summary, we developed a reliable method for synthesizing 10-methyl-aplog-1 (1) that 
could be applied to the production of several hundred milligrams of this potential medicinal lead.  
Notable features of this synthetic method include one-step hydroxyl-directed epoxidation of the 
homoallyl alcohol (5) and chemoselective oxidation of alkene (16) with a free secondary 
hydroxyl group.  An in vivo evaluation of the anticancer activity of 1 is currently in progress 





3. Experimental section 
 
3.1. General remarks 
     The following spectroscopic and analytical instruments were used:  Digital Polarimeter, 
P-2200 (Jasco, Tokyo, Japan); 1H, 13C NMR, Avance III 400 and Avance III 500 (Bruker, 
Germany); HPLC, Waters Model 600E with a Model 2487 UV detector; FAB-MS and 
HR-FAB-MS, JMS-600H and JMS-700 (JEOL, Tokyo, Japan); IR, FT/IR-470 Plus (Jasco, 
Tokyo, Japan).  HR-ESI-TOF-MS, Xevo G2-S QTof (Waters, MS, USA).  HPLC was carried 
out on YMC packed SIL SL12S05-1006WT, SIL SL12S05-2510WT, ODS-A 
AA12S05-1006WT (Yamamura Chemical Laboratory, Kyoto, Japan), and CHIRAL CEL 
OJ-RH (Daicel Corporation, Osaka, Japan).  Wakogel C-200 (silica gel, Wako Pure Chemical 
Industries, Osaka, Japan) and YMC A60-350/250 gel (ODS, Yamamura Chemical Laboratory, 
Kyoto, Japan) were used for column chromatography.  All other chemicals and reagents were 
purchased from chemical companies and used without further purification.  Compounds 8 and 
14 were synthesized as reported previously.16 
 
3.2. Synthesis of 1-(benzyloxy)-3-(3-bromopropyl)benzene (3). 
     m-Hydroxycinnamic acid (2) (20.0 g, 122 mmol) was treated in a manner similar to the 
method reported previously16 to afford the bromide (3) (33.8 g, 111 mmol, 91%) as a clear oil. 
 
3.3. Synthesis of ethyl 5-(3-(benzyloxy)phenyl)pentanoate (4). 
     The bromide (3) (33.8 g, 111 mmol) was treated in a manner similar to the method 
reported previously16 to afford the ester (4) (21.5 g, 68.8 mmol, 62%) as a clear oil. 
 
3.4. Synthesis of (3S,4R)-8-(3-(benzyloxy)phenyl)-3-methyloct-1-en-4-ol (5). 
     The ester (4) (21.5 g, 68.8 mmol) was subjected to partial reduction16 followed by 
Brown’s asymmetric crotylation11,14 as reported previously.  Four installments afforded 
homoallyl alcohol as a clear oil (5) (16.6 g, 51.2 mmol) in 74% yield. 
 
3.5. Synthesis of (2R,3R)-7-(3-(benzyloxy)phenyl)-2-((R)-oxiran-2-yl)heptan-3-ol (6). 
     The typical procedure used for the substrate-controlled epoxidation of the homoallyl 
alcohol (5) was as follows.  To a solution of 5 (3.63 g, 11.2 mmol) in CH2Cl2 (110 mL) were 
added vanadyl acetylacetonate (60 mg, 0.224 mmol) and 5.5 M t-BuOOH in decane (3.1 mL, 
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16.8 mmol) at rt.  While stirring for 7 h, additional VO (acac)2 (90 mg, 0.37 mmol) and 5.5 M 
t-BuOOH in decane (1.0 mL, 5.50 mmol) were added in two portions.  The reaction was 
quenched with 10% aq. Na2S2O3 (100 mL) and the mixture were extracted three times with 
EtOAc (200 mL x 1, 100 mL x 2).  The combined organic layers were washed with brine, 
dried over Na2SO4, filtered, and concentrated in vacuo.  The residue was purified by column 
chromatography (silica gel, 10% → 20% EtOAc/hexane) to afford an epoxyalcohol as a clear 
oil (6) (2.18 g, 6.41 mmol) and mixture (1.14 g) of the epoxyalcohol (6) and byproduct.  This 
procedure was repeated four times to afford 8.78 g of the epoxyalcohol (6) and 4.74 g of the 
mixture of epoxyalcohol (6) and byproduct.  The combined latter mixture was once again 
purified by column chromatography (silica gel, 10% → 20% EtOAc/hexane) to afford the 
epoxyalcohol (6) (1.21 g).  Finally, 10.0 g (29.4 mmol) of the epoxyalcohol (6) was obtained 
in 57% yield from 16.6 g (51.2 mmol) of the homoallyl alcohol (5).  1H NMR (400 MHz, 
297.7 K, CDCl3, 0.047 M) δ 0.96 (3H, d, J = 7.1 Hz), 1.30 (1H, m), 1.43–1.68 (6H, m), 2.14 
(1H, d, J = 3.6 Hz), 2.47 (1H, dd, J = 4.9, 2.8 Hz), 2.61 (2H, t, J = 7.6 Hz), 2.76 (1H, dd, J = 4.9, 
4.1 Hz), 2.91 (1H, ddd, J = 8.1, 4.1, 2.8 Hz), 3.65 (1H, m), 5.05 (2H, s), 6.78–6.82 (3H, m), 
7.19 (1H, t, J = 7.8 Hz), 7.32–7.45 (5H, m) ppm.  13C NMR (100 MHz, 298.0 K, CDCl3, 0.047 
M) δ 12.9, 25.1, 31.4, 34.3, 36.0, 42.2, 45.3, 54.7, 69.9, 75.1, 111.8, 115.1, 121.2, 127.5 (2C), 
127.9, 128.6 (2C), 129.2, 137.2, 144.4, 158.9 ppm.  IR (KBr) cm–1: 3461, 3033, 2934, 2862, 
1582, 1487, 1454, 1258, 1155, 1027, 756, 697.  HR-FAB-MS (matrix, m-nitrobenzyl alcohol) 
m/z: 340.2039 ([M]+, calcd for C22H28O3 340.2039).  [α]16.8D +10.8° (c = 0.53, CHCl3). 
 
3.6. Synthesis of 
(R)-2-((2R,3R)-7-(3-(benzyloxy)phenyl)-3-((4-methoxybenzyl)oxy)heptan-2-yl)oxirane (7). 
     The hydroxyl group of 6 (10.0 g, 29.4 mmol) was protected as the MPM ether, as 
reported previously11, in two trials to afford the MPM ether as a clear oil (7) (9.6 g, 20.9 mmol) 
in 71% yield. 
 
3.7. Synthesis of 
4-(2-(((2R,4S,5R,6R)-6-(4-(3-(benzyloxy)phenyl)butyl)-2-(4-methoxyphenyl)-5-methyl-1,3-d
ioxan-4-yl)methyl)-1,3-dithian-2-yl)-4-methylpentan-1-ol (9). 
     Coupling of the epoxide (7) (9.6 g, 20.9 mmol) with the dithiane (8) (11.8 g, 31.4 mmol) 
was performed on a several hundred milligram scale by a previously reported method to afford a 
coupling product (16.4 g, 19.6 mmol) in 94% yield.  DDQ-mediated oxidative acetalization, 
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followed by desilylation using a previously reported method,11,21 gave the alcohol as a clear oil 
(9) (12.3 g, 18.2 mmol) in 93% yield.  1H NMR: (500 MHz, 295.3 K, CDCl3, 0.017 M) δ 0.93 
(3H, d, J = 6.7 Hz), 1.18 (3H, s), 1.19 (3H, s), 1.44–1.78 (11H, m), 1.85 (1H, m), 1.94 (1H, m), 
2.38 (1H, dd, J = 16.2, 7.2 Hz), 2.46 (1H, d, J = 16.1 Hz), 2.60 (2H, m), 2.67–2.79 (2H, m), 
2.83–2.93 (2H, m), 3.46 (1H, m), 3.55 (2H, br.s), 3.79 (3H, s), 3.93 (1H, dd, J = 9.9, 7.1 Hz), 
5.04 (2H, s), 5.45 (1H, s), 6.75–6.82 (3H, m), 6.86 (2H, m), 7.19 (1H, t, J = 7.8 Hz), 7.32 (1H, 
m), 7.36–7.47 (6H, m) ppm.  13C NMR (125 MHz, 296.2 K, CDCl3, 0.017 M) δ 13.2, 22.5 (br), 
23.0 (br), 24.4, 24.9, 26.7, 27.6, 28.3, 31.4, 32.6, 32.9, 36.0, 38.9, 41.5, 44.5, 55.3, 63.7, 63.8, 
70.0, 80.3, 82.0, 99.5, 111.9, 113.4 (2C), 115.2, 121.2, 127.3 (2C), 127.5 (2C), 127.9, 128.6 
(2C), 129.2, 131.6, 137.3, 144.5, 158.9, 159.7 ppm.  IR (KBr) cm–1: 3421, 3032, 2936, 2860, 
1614, 1583, 1518, 1250, 1030, 755, 696.  HR-FAB-MS (matrix, m-nitrobenzyl alcohol): m/z: 
701.3335 ([M+Na]+, calcd for C40H54O5S2Na 701.3310).  [α]18.8D –3.4° (c = 0.58, CHCl3). 
 
3.8. Synthesis of 
(R)-7-(2-(((2R,4S,5R,6R)-6-(4-(3-(benzyloxy)phenyl)butyl)-2-(4-methoxyphenyl)-5-methyl-1
,3-dioxan-4-yl)methyl)-1,3-dithian-2-yl)-7-methyloct-1-en-4-ol (10). 
     The alcohol (9) (12.3 g, 18.2 mmol) was subjected to Parikh-Doering oxidation, followed 
by Maruoka’s asymmetric allylation on a 3-g scale, as reported previously,11,16 to afford the 
homoallyl alcohol as a clear oil (10) (7.89 g, 11.0 mmol) in 60% yield. 
 
3.9. Synthesis of 
(2S,3R,4R)-8-(3-(benzyloxy)phenyl)-1-(2-((R)-5-hydroxy-2-methyloct-7-en-2-yl)-1,3-dithian
-2-yl)-3-methyloctane-2,4-diol (11). 
     The typical procedure used for acid hydrolysis of the anisylidene acetal (10) was as 
follows.  To a solution of the acetal (10) (2.20 g, 3.06 mmol) in THF (120 mL) and H2O (12 
mL) was added TFA (6 mL) at 4 °C.  The mixture was heated at 50 °C for 23 h and then 
cooled to 4 °C.  The reaction was quenched with saturated aq. NaHCO3 (100 mL).  The 
mixture was extracted with EtOAc (100 mL x 3).  The combined organic layers were washed 
with brine, dried over Na2SO4, filtered, and concentrated in vacuo.  The residue was purified 
by column chromatography (silica gel, 5% → 20% → 50% EtOAc/hexane) to afford the triol as 
a clear oil (11) (760 mg, 1.27 mmol, 41%) and recovered acetal (10) (990 mg, 1.38 mmol, 45%).  
An additional 5.69 g of 10 was treated similarly in two portions.  Finally, 3.18 g (5.30 mmol) 
of the triol (11) was obtained from 7.89 g (11.0 mmol) of the acetal (10) in 48% yield.  1H 
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NMR (500 MHz, 296.3 K, CDCl3, 0.012 M) δ 0.84 (3H, d, J = 6.9 Hz), 1.14 (6H, s), 1.38–1.50 
(4H, m), 1.52–1.68 (6H, m), 1.67 (1H, d, J = 3.9 Hz, OH), 1.80 (1H, m), 1.90–2.01 (2H, m), 
2.13-2.20 (3H, m), 2.32 (1H, m), 2.60 (2H, m), 2.82–2.89 (2H, m), 2.93-3.01 (2H, m), 3.59–
3.61 (2H, m), 3.75 (1H, d, J = 2.5 Hz, OH), 4.30 (1H, m), 4.52 (1H, s, OH), 5.05 (2H, s), 5.13–
5.17 (2H, m), 5.82 (1H, m), 6.78–6.83 (3H, m), 7.18 (1H, t, J = 7.8 Hz), 7.31–7.47 (5H, m) ppm.  
13C NMR (125 MHz, 296.9 K, CDCl3, 0.012 M) δ 12.9, 22.4, 22.9 (br), 23.0, 25.0, 27.4, 27.5, 
31.6, 32.0, 32.7, 34.5, 36.1, 42.1, 42.3, 44.8, 45.6, 63.3, 70.0, 71.3, 73.9, 74.3, 111.9, 115.2, 
118.3, 121.2, 127.5 (2C), 127.9, 128.6 (2C), 129.2, 134.7, 137.3, 144.6, 158.9 ppm.  IR (KBr) 
cm–1: 3409, 3065, 3032, 2933, 2859, 1541, 1507, 1457, 1260, 1154, 1038, 695.  HR-FAB-MS 
(matrix, m-nitrobenzyl alcohol): m/z: 601.3356 ([MH]+, calcd for C35H53O4S2 601.3385).  
[α]19.3D +2.0° (c = 0.38, CHCl3). 
 
3.10. Synthesis of 
(2R,3S,4S,6R,8R)-8-allyl-2-(4-(3-(benzyloxy)phenyl)butyl)-3,11,11-trimethyl-1,7-dioxaspiro
[5.5]undecan-4-ol (12). 
     The typical procedure used for spiroketalization was as follows.  To a solution of a 
dithiane (11) (712 mg, 1.19 mmol) in MeCN (36 mL) and H2O (1.8 mL) was added Selectfluor® 
(1.05 g, 2.97 mmol) at 4 °C.  After stirring for 30 min at the same temperature, the reaction 
was quenched with saturated aq. NaHCO3 (40 mL).  The mixture was extracted with EtOAc 
(50 mL x 3), and the combined organic layers were washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo.  The residue was purified by column chromatography 
(silica gel, 5% → 15% EtOAc/hexane) to afford the desired spiroketal as a clear oil (12) (317 
mg, 0.644 mmol, 54%) and undesired spiroketal as a clear oil (13) (131 mg, 0.266 mmol, 22%).  
An additional 2.47 g of 11 was treated on a several hundred milligram scale in a similar manner 
to that described above.  A total of 1.47 g (2.99 mmol, 56%) of 12 and 577 mg (1.17 mmol, 
22%) of 13 were obtained from 3.18 g (5.30 mmol) of 11.  Compound 13: 1H NMR (500 MHz, 
295.0 K, CDCl3, 0.012 M) δ 0.90 (3H, s), 0.95 (3H, s), 0.95 (3H, d, J = 7.0 Hz), 1.14 (1H, dt, J 
= 13.0 Hz, 3.1 Hz), 1.31 (1H, d, J = 4.9 Hz, OH), 1.34–1.46 (4H, m), 1.58–1.74 (4H, m), 1.69 
(1H, dd, J = 13.0, 10.1 Hz), 1.80 (1H, dd, J = 13.2, 5.7 Hz), 1.88 (1H, td, J = 13.0, 5.2 Hz), 1.96 
(1H, m), 2.11 (1H, m), 2.16 (1H, m), 2.59 (2H, t, J = 7.4 Hz), 3.62 (1H, m), 3.78 (1H, m), 4.22 
(1H, m), 4.98–5.04 (2H, m), 5.05 (2H, s), 5.79 (1H, m), 6.78–6.81 (3H, m), 7.19 (1H, t, J = 7.8 
Hz), 7.30–7.45 (5H, m) ppm.  13C NMR (125 MHz, 296.0 K, CDCl3, 0.012 M) δ 11.6, 22.9, 
25.8, 26.7, 27.3, 31.3, 33.6, 33.9, 34.1, 36.0, 36.2, 36.8, 40.8, 64.4, 68.8, 70.0, 79.0, 102.6, 
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111.8, 115.3, 116.4, 121.2, 127.5 (2C), 127.9, 128.6 (2C), 129.2, 135.4, 137.2, 144.3, 158.9 ppm.  
IR (KBr) cm–1: 3384, 3067, 3033, 2934, 2858, 1584, 1456, 1259, 1155, 985, 917, 758, 740, 695.  
HR-ESI-TOF-MS (matrix, 50% MeOH/H2O containing 0.1% formic acid): m/z: 515.3124 
([M+Na]+, calcd for C32H45O4Na 515.3137).  [α]26.2D –9.6° (c = 0.36, CHCl3). 
     The undesired spiroketal (13) was subjected to the following acid catalyzed equilibrium 
reaction.  To a solution of 13 (577 mg, 1.17 mmol) in MeCN (20 mL) and CH2Cl2 (20 mL) 
was added PPTS (29.3 mg, 0.117 mmol) at rt.  After stirring for 30 min, the reaction was 
quenched with saturated aq. NaHCO3 (20 mL).  After the organic layer was separated, the 
aqueous layer was extracted with CH2Cl2 (40 mL x 2).  The combined organic layers were 
washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo.  The residue was 
purified by column chromatography (silica gel, 5% → 10% → 20% EtOAc/hexane) to afford 
the desired spiroketal (12) (420 mg, 0.854 mmol, 73%) and undesired spiroketal (13) (137 mg, 
0.278 mmol, 24%). 
 
3.11. Synthesis of 
(2R,3R,4S,6R,8R)-8-allyl-2-(4-(3-(benzyloxy)phenyl)butyl)-3,11,11-trimethyl-1,7-dioxaspiro
[5.5]undecan-4-yl (R)-4-(benzyloxy)-3-((4-methoxybenzyl)oxy)butanoate (15). 
     Condensation of the spiroketal (12) (737 mg, 1.50 mmol) with the acid (14) (544 mg, 
1.65 mmol) was performed in three portions by a previously reported method6 to afford the ester 
as a clear oil (15) (1.13 g, 1.40 mmol) in 93% yield. 
 
3.12. Synthesis of 
(2R,3R,4S,6R,8R)-8-allyl-2-(4-(3-(benzyloxy)phenyl)butyl)-3,11,11-trimethyl-1,7-dioxaspiro
[5.5]undecan-4-yl (R)-4-(benzyloxy)-3-hydroxybutanoate (16). 
     The typical procedure used was as follows.  To a vigorously stirred solution of the MPM 
ether (15) (514 mg, 0.639 mmol) in CH2Cl2 (30 mL) and pH 7.2 phosphate buffer (10 mL) was 
added DDQ (290 mg, 1.28 mmol) at rt.  After 1 h of stirring at rt, the mixture was poured into 
saturated aq. NaHCO3 (50 mL) and EtOAc (100 mL).  The organic layer was separated, and 
the aqueous layer was extracted with EtOAc (50 mL x 2).  The combined organic layers were 
washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo.  The residue was 
purified by column chromatography (silica gel, 10% → 20% EtOAc/hexane) to afford an 
alcohol (16) (401 mg, 0.586 mmol, 92%) as a clear oil.  An additional 616 mg (0.766 mmol) of 
15 was treated in a manner similar to that described above.  Finally, 832 mg (1.22 mmol) of 
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the alcohol (16) was obtained from 1.13 g (1.40 mmol) of the MPM ether (15) in 87% yield.  
1H NMR (500 MHz, 295.8 K, CDCl3, 0.017 M) δ 0.80 (3H, d, J = 6.90 Hz), 0.89 (3H, s), 0.93 
(3H, s), 1.25 (1H, m), 1.35–1.70 (10H, m), 1.70 (1H, dd, J = 15.2, 3.9 Hz), 2.12 (1H, dd, J = 
15.2, 2.7 Hz), 2.42 (2H, m), 2.54 (1H, dd, J = 16.3, 9.3 Hz), 2.59 (1H, t, J = 7.5 Hz), 2.62 (1H, 
dd, J = 16.3, 3.6 Hz), 3.46 (1H, dd, J = 9.6, 5.2 Hz), 3.51 (1H, dd, J = 9.6, 5.8 Hz), 3.62 (1H, m), 
3.88 (1H, d, J = 3.70 Hz, OH), 3.95 (1H, m), 4.25 (1H, m), 4.56 (2H, s), 4.97–5.01 (2H, m), 
5.05 (2H, s), 5.09 (1H, m), 5.75 (1H, m), 6.78–6.84 (3H, m), 7.19 (1H, t, J = 7.9 Hz), 7.27–7.47 
(10H, m) ppm.  13C NMR (125 MHz, 296.2 K, CDCl3, 0.017 M) δ 13.2, 23.6, 23.8, 24.5, 24.6, 
29.9, 31.4, 31.8, 32.4, 36.1, 36.2, 36.8, 39.4, 40.4, 67.0, 68.8, 70.0, 71.8, 72.0, 73.2, 73.5, 100.2, 
111.8, 115.2, 116.8, 121.2, 127.5 (2C), 127.7 (3C), 127.9, 128.4 (2C), 128.6 (2C), 129.2, 135.6, 
137.3, 138.1, 144.6, 158.9, 171.8 ppm.  IR (KBr) cm–1: 3473, 3065, 3032, 2935, 2859, 1732, 
1717, 1583, 1456, 1258, 1155, 915, 875, 739, 696.  HR-FAB-MS (matrix, m-nitrobenzyl 
alcohol): m/z: 684.4001 ([M]+, calcd for C43H56O7 684.4026).  [α]29.1D +47.2° (c = 0.57, 
CHCl3). 
 
3.13. Synthesis of 
2-((2R,6R,8R,9R,10S)-10-(((R)-4-(benzyloxy)-3-hydroxybutanoyl)oxy)-8-(4-(3-(benzyloxy)p
henyl)butyl)-5,5,9-trimethyl-1,7-dioxaspiro[5.5]undecan-2-yl)acetic acid (17). 
     The typical procedure used was as follows.  To a suspension of NaIO4 (1.0 g, 4.69 
mmol) in pH 7.2 phosphate buffer (40 mL) was added KMnO4 (92.6 mg, 0.586 mmol) in one 
portion.  After 15 min of stirring at rt under an Ar atmosphere, the mixture was added to a 
solution of the alkene (16) (401 mg, 0.586 mmol) in t-BuOH (40 mL).  The reaction mixture 
was stirred at rt for 45 min, and the reaction was quenched with Na2S2O3 (278 mg, 1.76 mmol).  
The resulting mixture was poured into EtOAc (100 mL) and H2O (100 mL).  The organic layer 
was separated, and the aqueous layer was extracted with EtOAc (80 mL x 2).  The combined 
organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo.  
The residue was purified by column chromatography (silica gel, 20% → 40% EtOAc/hexane 
containing 0.1% AcOH) to afford a seco-acid (17) (322 mg, 0.459 mmol, 78%) as a clear oil.  
An additional 431 mg (0.630 mmol) of 16 was treated in a manner similar to that described 
above.  Finally, 609 mg (0.867 mmol) of 17 was obtained from 832 mg (1.22 mmol) of 16 in 
71% yield.  1H NMR (400 MHz, 297.3 K, CDCl3, 0.032 M) δ 0.80 (3H, d, J = 8.9 Hz), 0.91 
(3H, s), 0.94 (3H, s), 1.30 (1H, m), 1.40–1.70 (9H, m), 1.75 (1H, m), 1.75 (1H, dd, J = 15.2, 3.9 
Hz), 2.10 (1H, dd, J = 15.2, 2.7 Hz), 2.47–2.53 (3H, m), 2.57–2.62 (2H, m), 2.72 (1H, dd, J = 
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15.0, 8.0 Hz), 3.48 (1H, dd, J = 9.6, 4.5 Hz), 3.50 (1H, dd, J = 9.6, 6.4 Hz), 3.95 (1H, m), 4.11 
(1H, m), 4.30 (1H, m), 4.57 (2H, s), 5.05 (2H, s), 5.12 (1H, m), 6.78–6.87 (3H, m), 7.19 (1H, t, 
J = 7.8 Hz), 7.28–7.45 (10H, m) ppm.  13C NMR (100 MHz, 297.5 K, CDCl3, 0.032 M) δ 13.2, 
23.7, 23.8, 24.4, 26.0, 30.1, 31.4, 31.5, 32.4, 36.0, 36.1, 36.9, 39.1, 41.2, 67.0, 69.3, 69.5, 69.9, 
71.2, 73.4, 73.6, 101.2, 111.8, 115.2, 121.2, 127.5 (2C), 127.9, 127.9, 128.0 (2C), 128.5 (2C), 
128.6 (2C), 129.2, 137.2, 137.5, 144.5, 158.9, 171.5, 173.0 ppm.  IR (KBr) cm–1: 3033, 2935, 
2861, 1733, 1717, 1685, 1577, 1457, 1258, 1058, 740, 696.  HR-FAB-MS (matrix, 
m-nitrobenzyl alcohol): m/z: 703.3876 ([MH]+, calcd for C42H55O9 703.3846).  [α]30.8D +38.8° 
(c = 0.37, CHCl3). 
 
3.14. Synthesis of 
(1R,3R,4R,5S,9R,13R)-9-((benzyloxy)methyl)-3-(4-(3-(benzyloxy)phenyl)butyl)-4,16,16-tri
methyl-2,6,10,17-tetraoxatricyclo[11.3.1.11,5]octadecane-7,11-dione (18). 
     The typical procedure used was as follows.  To a solution of the seco-acid (17) (322 mg, 
0.459 mmol) and Et3N (191 µL, 1.38 mmol) in toluene (23 mL), was added 
2,4,6-trichlorobenzoyl chloride (108 µL, 0.689 mmol) at rt.  The mixture was stirred at rt for 1 
h, and then diluted with toluene (100 mL).  The mixture was added dropwise to a solution of 
DMAP (840 mg, 6.89 mmol) in toluene (100 mL) over 15 min.  The anhydride flask was 
rinsed twice with toluene (5 mL) (each rinse was added in one portion to the reaction mixture).  
After an additional 2 h of stirring at rt, saturated aq. NaHCO3 (30 mL) was added and the 
organic layer was separated.  The aqueous layer was extracted with EtOAc (50 mL x 2), and 
the combined organic layers were washed with brine, dried over Na2SO4, filtered, and 
concentrated in vacuo.  The residue was purified by column chromatography (silica gel, 5% → 
10% EtOAc/hexane) to afford a lactone (18) (243 mg, 0.355 mmol, 77%) as a clear oil.  An 
additional 287 mg (0.408 mmol) of 17 was treated in a manner similar to that described above.  
Finally, 489 mg (0.714 mmol) of 18 was obtained from 609 mg (0.867 mmol) of 17 in 82% 
yield. 1H NMR (500 MHz, 295.0 K, CDCl3, 0.029 M) δ 0.77 (3H, d, J = 6.9 Hz), 0.85 (3H, s), 
0.96 (3H, s), 1.26–1.57 (10H, m), 1.68 (1H, m), 1.69 (1H, dd, J = 15.4, 4.0 Hz), 2.34 (1H, dd, J 
= 12.7, 10.9 Hz), 2.45–2.51 (2H, m), 2.60 (2H, t, J = 7.7 Hz), 2.78 (1H, dd, J = 17.1, 3.1 Hz), 
2.91 (1H, dd, J = 17.1, 11.5 Hz), 3.58 (1H, dd, J = 10.1, 5.5 Hz), 3.64 (1H, dd, J = 10.1, 3.6 Hz), 
3.84 (1H, m), 3.93 (1H, m), 4.49 (1H, d, J = 12.0 Hz), 4.57 (1H, d, J = 12.0 Hz), 5.03 (1H, br.s), 
5.05 (2H, s), 5.20 (1H, m), 6.79 (1H, dd, J = 8.2, 2.4 Hz), 6.82 (1H, d, J = 7.5 Hz), 6.86 (1H, 
br.s), 7.18 (1H, t, J = 7.9 Hz), 7.27–7.45 (10H, m) ppm.  13C NMR (125 MHz, 295.2 K, CDCl3, 
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0.029 M) δ 13.1, 21.4, 24.3, 26.0, 26.6, 27.3, 31.1, 32.3, 34.7, 36.1, 36.9, 36.9, 37.2, 42.7, 68.3, 
68.9, 69.9, 70.2, 70.6, 72.6, 73.5, 99.8, 111.8, 115.2, 121.3, 127.5 (2C), 127.7 (2C), 127.8 (2C), 
128.5 (4C), 129.1, 137.4, 137.8, 144.8, 158.9, 170.2 (2C) ppm.  IR (KBr) cm–1: 3032, 2935, 
2860, 1748, 1733, 1716, 1577, 1457, 1271, 1060, 753, 697.  HR-FAB-MS (matrix, 
m-nitrobenzyl alcohol): m/z: 685.3734 ([MH]+, calcd for C42H53O8 685.3740).  [α]30.1D +48.7° 
(c = 1.00, CHCl3). 
 
3.15. Synthesis of 
(1R,3R,4R,5S,9R,13R)-9-(hydroxymethyl)-3-(4-(3-hydroxyphenyl)butyl)-4,16,16-trimethyl-
2,6,10,17-tetraoxatricyclo[11.3.1.11,5]octadecane-7,11-dione (1). 
     The removal of the two benzyl groups of the lactone (18) (489 mg, 0.714 mmol) was 
performed in three portions by a method reported previously6 to afford a crude 1 (357 mg), 
which was purified by column chromatography (silica gel, 25% → 50% EtOAc/hexane) to 
afford 1 (287 mg, 0.596 mmol, 83%) as a clear oil.  The purity of 1 was more than 98%, which 
was confirmed by two diverse HPLC systems: YMC packed SIL SL12S05-1006WT using 
i-PrOH:CHCl3:hexane = 5:15:80 (flow rate of 1.0 mL/min; retention time of 11.0 min); YMC 
packed ODA-A AA12S05-1006WT using MeOH:H2O = 75:25 (flow rate of 1.0 mL/min; 
retention time of 13.8 min).  IR (KBr) cm–1: 3423, 3021, 2938, 2860, 1717, 1588, 1457, 1297, 
1276, 1060, 756, 696.  FAB-MS (matrix, m-nitrobenzyl alcohol): m/z 505 ([MH]+).  1H NMR 
and 13C NMR data coincided with those reported previously.11  A portion of 1 from above (10 
mg) was further purified by HPLC (column, YMC-Pack SIL SL12S05-2510WT; solvent, 
i-PrOH:CHCl3:hexane = 5:15:80; flow rate, 3.0 mL/min; pressure, 570 psi; retention time, 24.3 
min) to afford the material for confirmation of optical purity by measurement of specific optical 
rotation and chiral HPLC analysis.  [α]25.8D +67.6° (c 0.505, CHCl3: lit11, +76.2°).  Only one 
peak was detected by two diverse HPLC systems on CHIRAL CEL OJ-RH using MeOH:H2O = 
80:20 (flow rate of 0.5 mL/min; retention time of 19.2 min) and MeCN:H2O = 40:60 (flow rate 
of 0.5 mL/min; retention time of 26.2 min). 
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